Skip to content

Study · Not a test of the peptide alone · 2022

4 results

SOCS1, the feedback regulator of STAT1/3, inhibits the osteogenic differentiation of rat bone marrow mesenchymal stem cells.

Zhang Y, Jing Z, Cao X, Wei Q, He W, Zhang N, Liu Y, Yuan Q, Zhuang Z, Dong Y, Hong Z, Li J and 4 more

Show all authors

Li P, Zhang L, Wang H, Li W

Gene3 Feb 2022Cited by 9 (Europe PMC)

PMID35124149 (opens in a new tab)DOI10.1016/j.gene.2022.146190 (opens in a new tab)PepBankPUB-35124149
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Colivelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Colivelin.

  1. 01LabNot a test of Colivelin aloneIn vitro (cells)Mechanism

    In rat bone mesenchymal stem cells, STAT1/3 activation with colivelin increased SOCS1 expression.

    In plain wordsIn cells from rat bone marrow, activation with colivelin increased SOCS1 expression.

    Peptide
    Colivelin
    Outcome
    IncreaseSOCS1 expression
    Study

    ratn: not reported in source

    bone marrow mesenchymal stem cells
    Outcome group
    Receptor activity and mechanism · Musculoskeletal

    Source sentences

    Summary
    Further activation and deactivation of STAT1/3, by administrated with Colivelin and Nifuroxazide in Bone mesenchymal stem cells (BMSCs), increased and decreased SOCS1 expression, inhibited and promoted OD of BMSCs, respectively, as evidenced

    In this study, Colivelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Colivelin.

  2. 02LabNot a test of Colivelin aloneIn vitro (cells)Mechanism

    In rat bone mesenchymal stem cells, STAT1/3 activation with colivelin inhibited osteogenic differentiation.

    In plain wordsIn cells from rat bone marrow, activation with colivelin inhibited development into bone-forming cells.

    Peptide
    Colivelin
    Outcome
    DecreaseOsteogenic differentiation
    Study

    ratn: not reported in source

    bone marrow mesenchymal stem cells
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Further activation and deactivation of STAT1/3, by administrated with Colivelin and Nifuroxazide in Bone mesenchymal stem cells (BMSCs), increased and decreased SOCS1 expression, inhibited and promoted OD of BMSCs, respectively, as evidenced

    In this study, Colivelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Colivelin.

  3. 03LabNot a test of Colivelin aloneIn vitro (cells)Mechanism

    In rat bone mesenchymal stem cells, colivelin caused inflammation.

    In plain wordsIn cells from rat bone marrow, colivelin caused inflammation.

    Peptide
    Colivelin
    Outcome
    IncreaseInflammation
    Study

    ratn: not reported in source

    bone marrow mesenchymal stem cells
    Outcome group
    Inflammation markers · Musculoskeletal

    Source sentences

    Summary
    In addition, administration of Colivelin and Nifuroxazide caused and blocked inflammation and apoptosis of BMSCs.

    In this study, Colivelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Colivelin.

  4. 04LabNot a test of Colivelin aloneIn vitro (cells)Mechanism

    In rat bone mesenchymal stem cells, colivelin caused apoptosis.

    In plain wordsIn cells from rat bone marrow, colivelin caused programmed cell death.

    Peptide
    Colivelin
    Outcome
    IncreaseApoptosis
    Study

    ratn: not reported in source

    bone marrow mesenchymal stem cells
    Outcome group
    Cell viability and death · Musculoskeletal

    Source sentences

    Summary
    In addition, administration of Colivelin and Nifuroxazide caused and blocked inflammation and apoptosis of BMSCs.

    In this study, Colivelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Colivelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.